Potential options for patients with various characteristics (prior resistance and patient-related factors). √: Go, -: No-Go, ±: may be considered cautiously. The choices in the upper and lower panel may be combined. Len, lenalidomide; Bor, bortezomib; Dara, daratumumab; K, carfilzomib; CVD, cardiovascular; Dara, Rd, daratumumab, lenalidomide, dexamethasone; K-Rd, carfilzomib, lenalidomide, dexamethasone; Elo-Rd, elotuzumab, lenalidomide, dexamethasone; I-Rd, ixazomib, lenalidomide, dexamethasone; Isa-Kd56, isatuximab, carfilzomib, dexamethasone; Dara-Kd56, daratumumab, carfilzomib, dexamethasone; PVd, pomalidomide, bortezomib, dexamethasone; Dara, Pd, daratumumab, pomalidomide, dexamethasone; Isa, Pd, isatuximab, pomalidomide, dexamethasone; Elo, Pd, elotuzumab, pomalidomide, dexamethasone; S-Vd, selinexor, bortezomib, dexamethasone; Ven-Vd, venetoclax, bortezomib, dexamethasone; Pd-Cy, pomalidomide, dexamethasone, cyclophosphamide; KCyD, carfilzomib, cyclophosphamide, dexamethasone; K-Pd, carfilzomib, pomalidomide, dexamethasone; Sd, selinexor, dexamethasone; Belamaf, belantamab mafodotin.